Universal CMV Prophylaxis Mitigates the Risks of Basiliximab Induction in Heart Transplant Recipients at Intermediate Risk (R+) for Post-Transplant CMV Complications
2021 ◽
Vol 40
(4)
◽
pp. S117
2018 ◽
Vol 37
(4)
◽
pp. S355-S356
Keyword(s):
2018 ◽
Vol 37
(4)
◽
pp. S178
Keyword(s):
2021 ◽
Vol 40
(4)
◽
pp. S115
2021 ◽
Vol 40
(4)
◽
pp. S115-S116
Keyword(s):
2021 ◽
Vol 40
(4)
◽
pp. S116-S117
Keyword(s):
2021 ◽
Vol 23
(8)
◽
Keyword(s):
2020 ◽
Vol 39
(4)
◽
pp. S457-S458
2009 ◽
Vol 28
(12)
◽
pp. 1285-1291
◽
Keyword(s):